Holen Sie sich die Stockscreener-App
32.79
0.15%
0.05
Handel nachbörslich:
32.79
Schlusskurs vom Vortag:
$32.74
Offen:
$32.96
24-Stunden-Volumen:
528.87K
Relative Volume:
0.68
Marktkapitalisierung:
$1.94B
Einnahmen:
$184.42M
Nettoeinkommen (Verlust:
$-6.89M
KGV:
-220.81
EPS:
-0.1485
Netto-Cashflow:
$44.92M
1W Leistung:
+3.21%
1M Leistung:
-7.58%
6M Leistung:
+22.31%
1J Leistung:
+452.02%
1-Tages-Spanne:
$32.30
$33.82
1-Wochen-Bereich:
$30.66
$34.38
52-Wochen-Spanne:
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.79 | 1.94B | 184.42M | -6.89M | 44.92M | -0.1485 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - gurufocus.com
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - Markets Mojo
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
Stoke Therapeutics (NASDAQ: STOK) replaces KPMG with EY as auditor - stocktitan.net
Vanguard reports zero Stoke Therapeutics holdings (STOK) - stocktitan.net
Big Money Moves: What hedge funds are buying Stoke Therapeutics Inc2026 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Whale Trades: What is the earnings history of Stoke Therapeutics IncAnalyst Upgrade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Gains Recap: How does Stoke Therapeutics Inc score in quality rankings2026 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock - Investing.com Canada
Stoke Therapeutics Insider Sold Shares Worth $313,038, According to a Recent SEC Filing - MarketScreener
Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally - Yahoo Finance
(STOK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
FY2030 Earnings Estimate for STOK Issued By HC Wainwright - MarketBeat
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Stoke earnings loom as analysts bet big on Dravet therapy potential By Investing.com - Investing.com Australia
Stoke earnings loom as analysts bet big on Dravet therapy potential - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen - MarketBeat
Form 144 STOKE THERAPEUTICS INC For: 20 March By Investing.com - Investing.com Canada
Form 144 STOKE THERAPEUTICS INC For: 20 March - Investing.com
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Jonathan Allan plans sale of 9,293 RSUs at STOK (NASDAQ: STOK) - Stock Titan
Stoke Therapeutics stock price target raised to $60 by Canaccord on higher revenue assumptions - Investing.com Australia
Stoke Therapeutics Insider Sold Shares Worth $456,835, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics Insider Sold Shares Worth $285,901, According to a Recent SEC Filing - marketscreener.com
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ chief medical officer Ticho sells shares worth $413k - Investing.com India
Allan, Jonathan, Stoke Therapeutics general counsel, sells $285k in STOK - Investing.com India
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $60,517.54 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $58,790.81 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $209,539.24 in Stock - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) CFO Sells 2,382 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $145,041.52 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) CFO Sells $72,489.96 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 4,267 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 6,164 Shares - MarketBeat
Allan, Jonathan, Stoke Therapeutics general counsel, sells $285k in STOK By Investing.com - za.investing.com
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock - Investing.com
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):